Dr. Hebbar of CalciMedica Talks Auxora Clinical Trial Targeting COVID-19, CRAC, and More

trialsitenews's podcast

Today we have Dr. Hebbar from CalciMedica joining us today. Dr. Hebbar has 10+ years of clinical development and product development experience in both the pharmaceutical and diagnostics industries. Now, Privately held CalciMedica is dedicated to the discovery and development of novel small molecule drugs for the treatment of autoimmune disorders, organ transplant rejection, and other immune diseases. Founded in 2007 the San Diego-based company focuses on the discovery and development of CRAC channel inhibitor drugs. With the onset of the pandemic the company registered studies targeting severe COVID-19 pneumonia, a dangerous condition.